CN101283796B - Health product with walnut oil as matrix for treating osteoporosis and cardiovascular and cerebrovascular diseases - Google Patents
Health product with walnut oil as matrix for treating osteoporosis and cardiovascular and cerebrovascular diseases Download PDFInfo
- Publication number
- CN101283796B CN101283796B CN2008100583635A CN200810058363A CN101283796B CN 101283796 B CN101283796 B CN 101283796B CN 2008100583635 A CN2008100583635 A CN 2008100583635A CN 200810058363 A CN200810058363 A CN 200810058363A CN 101283796 B CN101283796 B CN 101283796B
- Authority
- CN
- China
- Prior art keywords
- walnut oil
- farnoquinone
- cardiovascular
- vitamin
- osteoporosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000019498 Walnut oil Nutrition 0.000 title claims abstract description 24
- 239000008170 walnut oil Substances 0.000 title claims abstract description 24
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 15
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 9
- 230000036541 health Effects 0.000 title claims abstract description 9
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 8
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 8
- 239000011159 matrix material Substances 0.000 title claims description 5
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 239000011259 mixed solution Substances 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 239000007901 soft capsule Substances 0.000 claims abstract description 5
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 claims description 32
- 239000007887 hard shell capsule Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 8
- 235000017471 coenzyme Q10 Nutrition 0.000 abstract description 3
- 230000037182 bone density Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 abstract description 2
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 abstract 3
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 abstract 3
- 235000019143 vitamin K2 Nutrition 0.000 abstract 3
- 239000011728 vitamin K2 Substances 0.000 abstract 3
- OCQQATZYCNAKQB-UQUNHUMXSA-N 2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 OCQQATZYCNAKQB-UQUNHUMXSA-N 0.000 abstract 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 abstract 1
- OCQQATZYCNAKQB-UHFFFAOYSA-N Vitamin K2(50) Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 OCQQATZYCNAKQB-UHFFFAOYSA-N 0.000 abstract 1
- 229940110767 coenzyme Q10 Drugs 0.000 abstract 1
- 239000007902 hard capsule Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- -1 terpenes tertiary alcohol Chemical class 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-naphthoquinone Chemical class C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 2
- AIDLAEPHWROGFI-UHFFFAOYSA-N 2-methylbenzene-1,3-dicarboxylic acid Chemical compound CC1=C(C(O)=O)C=CC=C1C(O)=O AIDLAEPHWROGFI-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000758789 Juglans Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- SGSOSQUCWDSWPG-UHFFFAOYSA-N hexane;nitromethane Chemical compound C[N+]([O-])=O.CCCCCC SGSOSQUCWDSWPG-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 239000010461 other edible oil Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000001443 terpenyl group Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a preparation with organic effective components and the functions of treating osteoporosis and cardiovascular and cerebrovascular diseases and health-care. 0.01g to 0.5g of vitamin K2 and 5g to 100g of coenzyme Q10 are mixed, 300g of walnut oil is heated and stirred at 40 ℃ to be dissolved, 599.5g to 694.99g of walnut oil is added under stirring, and the mixture is mixed evenly to prepare 1000g of mixed solution. The solution can be further packaged into soft capsule or hard capsule, and vitamin K2 is one or more of vitamin K2 to vitamin K2 (50). The invention can prevent and assist in treating cardiovascular diseases, and has the health care and treatment effects of increasing bone density and resisting osteoporosis.
Description
Technical field
The present invention relates to contain the preparation with treatment and health care of organic active ingredient.
Background technology
Osteoporosis is common disease, frequently-occurring disease; The medicine of treatment or prevention of osteoporosis has sex hormone, calcitonin, estrogenic agents and diphosphonate etc.; But these medicines all have certain side effect, as causing coronary heart disease, rhinitis, DVT and esophagus stimulation etc.In recent years research shows: one of reason of induced osteoporosis phenomenon is the deficiency owing to farnoquinone in the blood; Can not promote the generation of the solid factor protein matter C of factor III, IV, the V factor and anti-freezing, protein s; Cause the calcification protein (BGP) in the gelatine matter and organize γization protein (MGP) can't generate the bone sprout cell, thereby form osteoporosis.Farnoquinone, in generation of the bone sprout cell that promotes the formation sclerotin and the effectively breakage of inhibition osteocyte, treatment and prevention of osteoporosis disease aspect have the curative effect of uniqueness.Before this, we have proposed " a kind of synthetic method of producets in vitamin K 2 series " with application number 2007100660444, and it is with the 2-methyl isophthalic acid, and the 4-naphthoquinones and the long-chain terpenes tertiary alcohol are raw material, and with the 2-methyl isophthalic acid, the 4-naphthoquinones is through KBH
4Reduction forms quinhydrones; Again in nitromethane-n-hexane system; Make catalyst with anhydrous zinc chloride, BFEE, cuprous bromide; Under 40-43 ℃, carry out the Fridel-Crafts alkylated reaction with the long-chain terpenes tertiary alcohol, introduce the long-chain terpenyl, again with the synthetic corresponding farnoquinone of the aqueous isopropanol oxidation of ferric trichloride in the C3 position of quinhydrones.Because this invention reaction condition is gentle, yield is good, and reagent is recyclable and cost is cheap, and this invention has been applied in applicant's production.
Co-Q10 is in nineteen fifty-seven isolation identification from the cardiod plastochondria; Be the fat-soluble quinones that extensively exists in the organism, in the human body respiration chain, play an important role in proton displacement and the electronics transmission, can be used as cellular metabolism and cellular respiration activator; Or important antioxidants and nonspecific immunity strengthening agent; Have the accelerating oxidation phosphorylation reaction, protection biofilm structure integrality is having unique curative effect aspect prevention and the treatment angiocardiopathy.The human body synthesizing coenzyme Q 10 began to descend year by year after 20 years old, and the Q10 content in the middle aged human body is merely the half the of young people or still less.In edible oil, add Co-Q10 protection the elderly heart, in application for a patent for invention number 200410010326.9 " a kind of health-care edible oils that are rich in Co-Q10 ", propose.In addition, application number 00102765.4 " a kind of Coenzyme Complex Q10 nutrient and healthcare products " has been noticed Co-Q10 and the issuable effect of Combination application as the vitamin A of active oxygen radical scavenger, C, E.And walnut oil contains the unrighted acid of 80-95%, the content of omega-fatty acid, ω-6 aliphatic acid be other edible oils kind, be 3 to 4 times of common rapeseed oil content.Especially, walnut oil is rich in trace elements such as vitamin A, B1, B2, C, E and Ca, Mg, itself has the plant chemical ingredient that overcomes the Co-Q10 negative consequence.
Therefore, have different bioactive compositions with above-mentioned several kinds for human body and prepare by a certain percentage, do not propose to the health care or the therapeutic combination of senile osteoporosis and cardiovascular and cerebrovascular disease.
Summary of the invention
The object of the present invention is to provide the food or the Ricipe for health care food that common osteoporosis and cardiovascular and cerebrovascular disease are had treatment and health care.
The present invention accomplishes in the following manner:
0.01g～0.5g farnoquinone is mixed with 5g～100g Co-Q10, after 40 ℃ of heated and stirred dissolvings, add 599.5 g～694.99g walnut oil in stirring down again, mix, be made into the 1000g mixed solution with the 300g walnut oil.
That described solution can further be packaged into is soft, hard shell capsules or cellulose capsule, makes 2000 altogether, every dress 0.5g, and every farnoquinone content is 5ug～250ug, Co-Q10 content is 2.5mg～50mg.
Described farnoquinone is that farnoquinone (5) arrives one or more in the farnoquinone (50).
Above-mentioned walnut oil is for being that raw material obtains through squeezing or extraction with the walnut kernel, is rich in unrighted acid and vitamin A thereof, B1, B2, the C of 65-95%, the product of E.
The present invention has following beneficial effect:
Farnoquinone and Co-Q10 itself is human body endogenous product, and it has no side effect, and takes safety, its good curing and angiocardiopathy preventing, and experiment is confirmed by lots of clinical to increase bone density, anti-osteoporosis activity.The present invention is a matrix with the health food walnut oil that has an abundant nutrition for treatment and angiocardiopathy preventing; Utilize the applicant to produce the unique conditions of farnoquinone series of products; And in invention prescription through adding exogenous human body Co-Q10; Can make the above-mentioned substance content in the human body maintain normal level; Thereby reach prevention and supplemental treatment because the above-mentioned substance content that the growth at age causes reduces the various diseases that causes, good health care effect and certain treatment curative effect can be arranged sufferers of osteoporosis face, cardiovascular and cerebrovascular disease patient, particularly postmenopausal women, mental worker and the elderly.
Below through embodiment the present invention is further specified, but the present invention does not receive the restriction of the embodiment that lifts.
The specific embodiment
Embodiment 1: 0.4g farnoquinone (20) is mixed with the 30g Co-Q10, after 40 ℃ of heated and stirred dissolvings, add the 669.6g walnut oil in stirring down with the 300g walnut oil again, mix, be made into the 1000g mixed solution.
Embodiment 2: in clean workplace, the lucifuge operation mixes 0.01g farnoquinone (20) with the 100g Co-Q10; After 40 ℃ of heated and stirred dissolvings, add the 599.9g walnut oil in stirring down with about 300g walnut oil again, mix; Be made into the 1000g mixed solution, in the impouring hard shell capsules.Every dress 0.5g, every farnoquinone content is 5ug, and Co-Q10 content is 50mg, and packing promptly gets.
Embodiment 3: in clean workplace, the lucifuge operation mixes 0.1g farnoquinone (35) with the 40g Co-Q10; After 40 ℃ of heated and stirred dissolvings, add the 659.9g walnut oil in stirring down with about 300g walnut oil again, mix; Be made into the 1000g mixed solution, be pressed into soft capsule, every dress 0.5g; Every farnoquinone content is 250ug, and Co-Q10 content is 2.5mg, and packing promptly gets.
Embodiment 4: in clean workplace, the lucifuge operation mixes 0.3g farnoquinone (45) with the 60g Co-Q10; After 40 ℃ of heated and stirred dissolvings, add the 639.7g walnut oil in stirring down with about 300g walnut oil again, mix; Be made into the 1000g mixed solution, be pressed into soft capsule, every dress 0.5g; Every farnoquinone content is 250ug, and Co-Q10 content is 2.5mg, and packing promptly gets.
Embodiment 5: in clean workplace, the lucifuge operation mixes 0.2g farnoquinone (5) and 0.3g K2 (35) with the 5g Co-Q10; After 40 ℃ of heated and stirred dissolvings, add the 694.5g walnut oil in stirring down with about 300g walnut oil again, mix; Be made into the 1000g mixed solution, be pressed into soft capsule, every dress 0.5g; Every farnoquinone content is 250ug, and Co-Q10 content is 2.5mg, and packing promptly gets.
In the test of observation property; The capsule finished product that provides according to embodiment 2,3; Through two routine congestive heart failures, coronary heart disease, angina pectoris initial stage patient, seven routine myocardial ischemias, hyperpietic's morning and evening every day hard shell capsules, edible tri month its symptom all has stable or improves.By above dosage, two routine sufferers of osteoporosis face edible tris are after individual month, and its symptom all has improvement.
Claims (2)
1. be the treatment osteoporosis of matrix and the health products of cardiovascular and cerebrovascular diseases with the walnut oil, it is characterized in that:
0.01g～0.5g farnoquinone is mixed with 5g～100g Co-Q10, after 40 ℃ of heated and stirred dissolvings, add 599.5g～694.99g walnut oil in stirring down again, mix, be made into the 1000g mixed solution with the 300g walnut oil;
Wherein, farnoquinone is that farnoquinone (5) arrives one or more in the farnoquinone (50).
2. according to claim 1 is the treatment osteoporosis of matrix and the health products of cardiovascular and cerebrovascular diseases with the walnut oil; It is characterized in that further being packaged into soft capsule or hard shell capsules; Make 2000 altogether; Every dress 0.5g, every farnoquinone content is 5 ug～250ug, Co-Q10 content is 2.5mg～50mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100583635A CN101283796B (en) | 2008-05-08 | 2008-05-08 | Health product with walnut oil as matrix for treating osteoporosis and cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100583635A CN101283796B (en) | 2008-05-08 | 2008-05-08 | Health product with walnut oil as matrix for treating osteoporosis and cardiovascular and cerebrovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101283796A CN101283796A (en) | 2008-10-15 |
| CN101283796B true CN101283796B (en) | 2012-05-30 |
Family
ID=40056375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100583635A Active CN101283796B (en) | 2008-05-08 | 2008-05-08 | Health product with walnut oil as matrix for treating osteoporosis and cardiovascular and cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101283796B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101849971A (en) * | 2010-06-08 | 2010-10-06 | 玉溪健坤生物药业有限公司 | Soft capsule containing coenzyme Q10 and preparation method and application thereof |
| EP2605663A1 (en) * | 2010-08-17 | 2013-06-26 | Chr. Hansen A/S | Lactococcus lactis strain with high vitamin k2 production |
| CN102488207A (en) * | 2011-12-14 | 2012-06-13 | 广州善元堂医药科技有限公司 | Coenzyme Q10 soft capsule and its preparation method |
| CN103142640A (en) * | 2013-04-01 | 2013-06-12 | 李拖平 | Health care product containing vitamin K2 and having functions of preventing and treating brittle-bone disease |
| CN104189553A (en) * | 2014-07-26 | 2014-12-10 | 广东医学院 | Application of the composition containing coenzyme Q10 and vegetable oil in the preparation of health food and medicine for preventing osteoporosis |
| CN105902840B (en) * | 2016-04-12 | 2019-09-03 | 广东润和生物科技有限公司 | Cardiovascular disease and the drug of dementia and preparation method thereof caused by a kind of prevention and treatment Apolipoprotein E-deficient |
| CN108294308A (en) * | 2018-01-17 | 2018-07-20 | 上海茂久中医药科技有限公司 | A kind of white flower loropetalum chinense health products and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1278616C (en) * | 2004-06-08 | 2006-10-11 | 于新华 | Healthy edible oil with coenzyme Q10 |
-
2008
- 2008-05-08 CN CN2008100583635A patent/CN101283796B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1278616C (en) * | 2004-06-08 | 2006-10-11 | 于新华 | Healthy edible oil with coenzyme Q10 |
Non-Patent Citations (1)
| Title |
|---|
| 苏林.维生素E能否用于防治骨质疏松.《中华医学信息导报》.1994,第14页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101283796A (en) | 2008-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101283796B (en) | Health product with walnut oil as matrix for treating osteoporosis and cardiovascular and cerebrovascular diseases | |
| Kapoor et al. | Coenzyme Q10-a novel molecule | |
| JPH05505935A (en) | Extended release formulation of vitamins, minerals and other beneficial supplements | |
| Glade | A 21st century evaluation of the safety of oral vitamin D | |
| CN103385493A (en) | Healthy food using Antarctic krill oil as main ingredient | |
| CN101849971A (en) | Soft capsule containing coenzyme Q10 and preparation method and application thereof | |
| JP5198858B2 (en) | Carrier for enteral administration | |
| CN101558843A (en) | Method for preparing a propolis, bee pollen and royal jelly nutritive mixture | |
| CN101283797B (en) | Health products for promoting the intelligence and strengthening the brain using walnut oil as matrix | |
| EP2257300B1 (en) | Formulas comprising calcium, magnesium, zinc, and vitamin d3 for the prevention and amelioration of osteoporosis | |
| KR101517095B1 (en) | Periodontal diseases treatment and prevention composition using the natural extracts | |
| US20070026091A1 (en) | Preparation and Administration of Jojoba Product for Reducing Weight, Fat and Blood Lipid Levels and for the Prevention and Treatment of Cancer | |
| CN100539999C (en) | Compound preparation for weight loss, fat reduction, blood sugar reduction, blood pressure reduction, and prevention and treatment of osteoporosis | |
| US11596166B2 (en) | Compositions and methods for treating aging and/or improving human health | |
| US20130022673A1 (en) | Enhancement of magnesium uptake in mammals | |
| CN101194913A (en) | Natural seal oil compression biological preparation for treating hyperlipidemia and technique of preparing the same | |
| TW201031343A (en) | A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement | |
| US20100323031A1 (en) | Synergistic combination to enhance blood glucose and insulin metabolism | |
| CN1262284C (en) | Health care product of hippophae rhamnoides oil | |
| CN102151285B (en) | Neutral calcium supplement preparation | |
| CN101108000B (en) | Addition-application method of functional properties fat planting food mixture | |
| EP2606900A1 (en) | Enhancement of magnesium uptake in mammals | |
| CN101331948A (en) | Compound health products containing coenzyme Q10 and spirulina | |
| US20160022594A1 (en) | Soft gel encapsulation | |
| CN102578572A (en) | Mineral and vitamin nutritional supplement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20081015 Assignee: Kunming Goodkwang Health-Care Food Co., Ltd. Assignor: Kunming Yunda Medicine Development Co., Ltd. Contract record no.: 2013530000020 Denomination of invention: Health products for osteoporosis and cardio-cerebrovascular disease using walnut oil as matrix Granted publication date: 20120530 License type: Exclusive License Record date: 20130321 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Kunming Goodkwang Health-Care Food Co., Ltd. Assignor: Kunming Yunda Medicine Development Co., Ltd. Contract record no.: 2013530000020 Date of cancellation: 20150408 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160616 Address after: 515000 Guangdong province Haojiang District Shantou City Binhai Industrial Park Road Huatai Office Building Room 101 Patentee after: Guangdong Gusheng Medical Technology Co., Ltd. Address before: 650032, No. 998, village head, Longquan Road, Wuhua District, Yunnan, Kunming Patentee before: Kunming Yunda Medicine Development Co., Ltd. |